GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7%

Tue, 23 Oct

GSK PHARMA has announced its results for the quarter ended September 2018. Here is a detailed performance review of the same:

GSK PHARMA Quarterly Financials

Year-on-Year Performance:

• The company's operating income during the quarter fell 2.4% on a year-on-year (YoY) basis. The expenses were up by 1.1% YoY during the same period.
• The company's operating profit declined by 22.3% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 18.8% in 2QFY19 as against 23.6% in 2QFY18.
• Depreciation charges and finance costs increased by 48.8% YoY and 0.0% YoY, respectively.
• Other income increased by 54.2% YoY during the quarter.
• Net profit for the quarter declined by 22.7% YoY. Net profit margins during the quarter declined from 15.4% in 2QFY18 to 12.1% in 2QFY19.

Quarter-on-Quarter Performance:

• The company's operating income during the quarter grew 11.0% on a quarter-on-quarter (QoQ) basis. The expenses were up by 9.4% QoQ during the same period.
• The company's operating profit increased by 16.1% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 18.8% in 2QFY19 as against 18.0% in 1QFY18.
• Net profit for the quarter increased by 13.7% QoQ, while net profit margins increased from 11.8% in 1QFY18 to 12.1% in 2QFY19.

To see how GSK PHARMA has performed over the last eight quarters, please visit here.

GSK PHARMA Share Price Performance

Over the last one year, GSK PHARMA share price has moved up from Rs 1,217.9 to Rs 1,355.0, registering a Gain of Rs 137.1 or around 11.3%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,438.9 (down 0.5%). Over the last one year it has moved up from 14,047.3 to 14,438.9, a gain of 392 points (up 2.8%).

Overall, the S&P BSE SENSEX is up 4.6% over the year.

Current Valuations

At the current price of Rs 1,355.0, the price to earnings (P/E) ratio of GSK PHARMA stands at 59.7 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 11.2 times.